- Home
- SOTK vs ANL Comparison
SOTK vs ANL Comparison
Compare SOTK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- ANL
- Stock Information
- Founded
- SOTK 1975
- ANL 2004
- Country
- SOTK United States
- ANL Cayman Islands
- Employees
- SOTK N/A
- ANL N/A
- Industry
- SOTK Industrial Machinery/Components
- ANL
- Sector
- SOTK Technology
- ANL
- Exchange
- SOTK Nasdaq
- ANL Nasdaq
- Market Cap
- SOTK 52.1M
- ANL 61.8M
- IPO Year
- SOTK 1987
- ANL 2023
- Fundamental
- Price
- SOTK $4.61
- ANL $1.40
- Analyst Decision
- SOTK Hold
- ANL Hold
- Analyst Count
- SOTK 1
- ANL 1
- Target Price
- SOTK N/A
- ANL N/A
- AVG Volume (30 Days)
- SOTK 50.4K
- ANL 9.0K
- Earning Date
- SOTK 10-14-2025
- ANL 11-07-2025
- Dividend Yield
- SOTK N/A
- ANL N/A
- EPS Growth
- SOTK 6.63
- ANL N/A
- EPS
- SOTK 0.10
- ANL N/A
- Revenue
- SOTK $20,607,030.00
- ANL N/A
- Revenue This Year
- SOTK $2.67
- ANL N/A
- Revenue Next Year
- SOTK $8.20
- ANL N/A
- P/E Ratio
- SOTK $47.93
- ANL N/A
- Revenue Growth
- SOTK N/A
- ANL N/A
- 52 Week Low
- SOTK $3.23
- ANL $1.10
- 52 Week High
- SOTK $6.05
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- SOTK 59.63
- ANL 36.83
- Support Level
- SOTK $4.36
- ANL $1.30
- Resistance Level
- SOTK $4.96
- ANL $1.59
- Average True Range (ATR)
- SOTK 0.39
- ANL 0.11
- MACD
- SOTK -0.01
- ANL -0.02
- Stochastic Oscillator
- SOTK 47.57
- ANL 32.56
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.